Meeting
2022 ASCO Annual Meeting
Targeting signaling pathways vulnerabilities for the treatment of IKZF1-deleted ph-negative B lymphoblastic leukemia.
Authors
Rohit Gupta
Baylor College of Medicine, Houston, TX
Rohit Gupta , Jason H. Rogers , Xin Long , Rogelio Aguilar , Geraldo Medrano , Jaime Reyes , Michele Redell , Margaret A. Goodell , Rachel E. Rau
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7033)
DOI
10.1200/JCO.2022.40.16_suppl.7033
Abstract #
7033
Poster Bd #
264
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Physical and emotional quality of life in children with B-acute lymphoblastic leukemia randomized to every 4- vs. 12-week vincristine/dexamethasone during maintenance: Children’s Oncology Group AALL0932.
First Author: Lyn M. Balsamo
Poster
2024 ASCO Breakthrough
Analysis of heterochromatin remodeling as a mechanism of radiotherapy (RT) resistance through molecular profiling of radioresistant (RR) head and neck (HNC) and prostate cancers (PCa).
First Author: Evelyn Tan
Poster
2024 ASCO Annual Meeting
Independent blinded validation of an AI-based digital histology classifier for prostate cancer recurrence and metastasis risk prediction.
First Author: Magdalena Fay
Poster
2024 ASCO Annual Meeting
Dissecting the significance of ACP1 gene alterations in prostate cancer (PCa).
First Author: Nour Abdallah